Literature DB >> 22805157

Mechanically ventilated children with 2009 pandemic influenza A/H1N1: results from the National Pediatric Intensive Care Registry in Japan.

Natsuko Tokuhira1, Nobuaki Shime, Miho Inoue, Tatsuya Kawasaki, Yoshio Sakurai, Norimasa Kurosaka, Ikuya Ueta, Satoshi Nakagawa.   

Abstract

OBJECTIVE: To outline the characteristics, clinical course, and outcome of pediatric patients requiring mechanical ventilation with influenza A/H1N1 infection in Japan.
DESIGN: Prospective case registry analysis.
SETTING: Eleven pediatric or general intensive care units in Japan. PATIENTS: Consecutive patients infected with A/H1N1, aged from 1 month to 16 yrs old admitted to the intensive care unit for mechanical ventilation between July 2009 and March 2010.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Eighty-one children, aged 6.3 [0.8-13.6] (median [interquartile range]) years, were enrolled. Seventy-four (91%) had mechanical ventilation with tracheal intubation. Median duration of mechanical ventilation was 4 days (range 0.04-87) and 18 patients (23%) required mechanical ventilation >7 days. Two patients (2%) required extracorporeal membrane oxygenation. The in-hospital mortality was 1%. Forty-one patients (50%) had at least one underlying chronic condition, including 31 with asthma. Associated clinical symptoms and diagnosis were as follows: acute respiratory distress syndrome (9%), asthma or bronchitis (37%), pneumonia (68%) with 8 (14%) having bacterial pneumonia, neurological symptoms (32%), myocarditis (2%), and rhabdomyolysis (1%). Therapeutic interventions include inotropic support (21%), methylprednisolone therapy (33%), and antimicrobial therapy (88%). Multivariate analysis revealed that inotropic support was the only statistically significant factor associated with mechanical ventilation for more than a week (odds ratio 5.5, 95% confidence interval 1.5-20.5, p = .005).
CONCLUSIONS: The clinical presentations of pediatric patients requiring mechanical ventilation for A/H1N1 in Japan were diverse. In-hospital mortality of this population was remarkably low. Rapid access to medical facilities in combination with early administration of antiviral agents may have contributed to the low mortality in this population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22805157     DOI: 10.1097/PCC.0b013e31824fbb10

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  6 in total

Review 1.  Influenza-associated neurological complications.

Authors:  Jenny P Tsai; Andrew J Baker
Journal:  Neurocrit Care       Date:  2013-02       Impact factor: 3.210

2.  Acute respiratory distress syndrome in a child with severe epileptic disorder treated successfully by extracorporeal membrane oxygenation: a case report.

Authors:  Nobuyuki Nosaka; Shingo Ichiba; Kohei Tsukahara; Emily Knaup; Kumiko Hayashi; Shingo Kasahara; Yoshinori Kobayashi; Makio Oka; Katsuhiro Kobayashi; Harumi Yoshinaga; Yoshihito Ujike
Journal:  BMC Pediatr       Date:  2015-04-01       Impact factor: 2.125

Review 3.  Viral Infection in the Development and Progression of Pediatric Acute Respiratory Distress Syndrome.

Authors:  Steven Nye; Richard J Whitley; Michele Kong
Journal:  Front Pediatr       Date:  2016-11-24       Impact factor: 3.418

4.  Letter: Neurological Implications of COVID-19 and Lessons Learned From Prior Epidemics and Pandemics.

Authors:  Badih J Daou; Sravanthi Koduri; Gregory Palmateer; B Gregory Thompson; Neeraj Chaudhary; Joseph J Gemmete; Aditya S Pandey
Journal:  Neurosurgery       Date:  2020-08-01       Impact factor: 4.654

5.  Does Asthma Increase the Mortality of Patients with COVID-19?: A Systematic Review and Meta-Analysis.

Authors:  Yuanyuan Wang; Jingjing Chen; Wei Chen; Ling Liu; Mei Dong; Juan Ji; Die Hu; Nianzhi Zhang
Journal:  Int Arch Allergy Immunol       Date:  2020-09-22       Impact factor: 2.749

Review 6.  Neurological events related to influenza A (H1N1) pdm09.

Authors:  Graciela Cárdenas; José Luis Soto-Hernández; Alexandra Díaz-Alba; Yair Ugalde; Jorge Mérida-Puga; Marcos Rosetti; Edda Sciutto
Journal:  Influenza Other Respir Viruses       Date:  2014-05       Impact factor: 4.380

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.